Protein Kinase C Phosphorylates RGS2 and Modulates Its Capacity for Negative Regulation of Galpha 11 Signaling*

Michelle L. Cunningham, Gary L. Waldo, Susanne HollingerDagger , John R. HeplerDagger , and T. Kendall Harden§

From the Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7365 and the Dagger  Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322-3090

Received for publication, August 23, 2000, and in revised form, October 11, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

RGS proteins (regulators of G protein signaling) attenuate heterotrimeric G protein signaling by functioning as both GTPase-activating proteins (GAPs) and inhibitors of G protein/effector interaction. RGS2 has been shown to regulate Galpha q-mediated inositol lipid signaling. Although purified RGS2 blocks PLC-beta activation by the nonhydrolyzable GTP analog guanosine 5'-O-thiophosphate (GTPgamma S), its capacity to regulate inositol lipid signaling under conditions where GTPase-promoted hydrolysis of GTP is operative has not been fully explored. Utilizing the turkey erythrocyte membrane model of inositol lipid signaling, we investigated regulation by RGS2 of both GTP and GTPgamma S-stimulated Galpha 11 signaling. Different inhibitory potencies of RGS2 were observed under conditions assessing its activity as a GAP versus as an effector antagonist; i.e. RGS2 was a 10-20-fold more potent inhibitor of aluminum fluoride and GTP-stimulated PLC-beta t activity than of GTPgamma S-promoted PLC-beta t activity. We also examined whether RGS2 was regulated by downstream components of the inositol lipid signaling pathway. RGS2 was phosphorylated by PKC in vitro to a stoichiometry of approximately unity by both a mixture of PKC isozymes and individual calcium and phospholipid-dependent PKC isoforms. Moreover, RGS2 was phosphorylated in intact COS7 cells in response to PKC activation by 4beta -phorbol 12beta -myristate 13alpha -acetate and, to a lesser extent, by the P2Y2 receptor agonist UTP. In vitro phosphorylation of RGS2 by PKC decreased its capacity to attenuate both GTP and GTPgamma S-stimulated PLC-beta t activation, with the extent of attenuation correlating with the level of RGS2 phosphorylation. A phosphorylation-dependent inhibition of RGS2 GAP activity was also observed in proteoliposomes reconstituted with purified P2Y1 receptor and Galpha qbeta gamma . These results identify for the first time a phosphorylation-induced change in the activity of an RGS protein and suggest a mechanism for potentiation of inositol lipid signaling by PKC.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A variety of hormone and neurotransmitter receptors transduce signals through heterotrimeric G proteins. In their inactive state, G proteins exist as heterotrimers consisting of alpha , beta , and gamma  subunits with GDP bound to Galpha . Upon agonist occupation, the receptor promotes GDP/GTP exchange, and the active GTP-bound Galpha subunit and Gbeta gamma dissociate to interact with target effector proteins. Signaling is terminated by the hydrolysis of GTP to GDP and the subsequent formation of the heterotrimer. Therefore, the magnitude and duration of signaling is determined by the length of time Galpha remains in the active GTP-bound conformation.

A recently identified family of proteins termed RGS (regulators of G protein signaling) proteins interact directly with Galpha subunits to decrease the lifetime of the active GTP-bound complex (1-4). RGS proteins attenuate heterotrimeric G protein1 signaling by functioning as both GTPase-activating proteins (GAPs) (5, 6) and inhibitors of G protein/effector interaction (6, 7). In vitro studies illustrate that RGS2 interacts with and functions as a GAP for Galpha q (8), and in vivo studies demonstrate that RGS2 is a more potent inhibitor of Galpha q signaling than is RGS4 in transfected cells (9). Members of the Gq family of G proteins transmit signals from numerous cell surface receptors, leading to activation of PLC-beta isozymes and subsequent cleavage of membrane phosphatidylinositol 4,5-bisphosphate to the second messengers inositol 1,4,5-trisphosphate and diacylglycerol (10). Inositol 1,4,5-trisphosphate initiates release of calcium from endoplasmic reticulum stores, and diacylglycerol, in conjunction with calcium and phospholipids, activates PKC (10). Purified RGS2 has been shown to attenuate GTPgamma S-stimulated inositol lipid signaling in reconstitution studies with both purified Galpha q and NG-108 cell membranes (7). However, the capacity of RGS2 to modify inositol lipid signaling under conditions where GTPase-promoted hydrolysis was operative was not established. Utilizing the well characterized turkey erythrocyte model of inositol lipid signaling (11-18), we have determined the effects of RGS2 on both GTP and GTPgamma S-stimulated Galpha 11 activation of PLC-beta t. Moreover, our results indicate that PKC promotes phosphorylation of RGS2, both in intact mammalian cells in response to PMA and in vitro with purified kinase. This modification in vitro inhibits the capacity of RGS2 to attenuate PLC-beta t activation and significantly reduces RGS2-promoted GAP activity.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Hexahistidine-tagged human RGS2 was purified after expression in Escherichia coli as described previously (19). PS and 1,2-dioleoyl-sn-glycerol were obtained from Avanti Polar Lipids (Alabaster, AL). 2MeSATP and isoproterenol were purchased from RBI (Natick, MA). GTP, GTPgamma S, FuGENE transfection reagent, and PKC (calcium- and phospholipid-dependent enzyme) purified from bovine brain were purchased from Roche Molecular Biochemicals. Calyculin A, PKC (catalytic subunit) purified from rat brain, and PKC isoforms (alpha , beta 1, beta 2, and gamma ) were obtained from Calbiochem. myo-[3H]inositol was purchased from American Radiolabeled Chemicals (St. Louis, MO). Histidine-tagged (His10) RGS2 plasmid DNA (pcDNA3.1(-); Invitrogen) was constructed from a bacterial RGS2 expression construct (provided by Dr. Scott Heximer) via standard cloning techniques. Ni2+-NTA resin and the penta-His monoclonal antibody were purchased from Qiagen (Valencia, CA).

[3H]Inositol Labeling of Turkey Erythrocytes and Membrane Preparation-- Turkey erythrocytes were collected and washed as described previously (12). Washed erythrocytes were radiolabeled overnight in inositol-free DMEM supplemented with myo-[3H]inositol (500 µCi/ml packed cells) at 37 °C in a 95% O2, 5% CO2 atmosphere with rapid stirring. Erythrocytes were lysed hypotonically in 40 ml of ice-cold lysis buffer (5 mM NaH2PO4, 5 mM MgCl2, 1 mM EGTA, pH 7.4), and membranes were isolated by centrifugation at 13,500 × g for 10 min. The membranes were washed with lysis buffer and 10 mM Hepes, pH 7.0, and then resuspended (2 ml/ml packed erythrocytes) in 10 mM Hepes, pH 7.0, for use in the PLC assay.

Assay of Phospholipase C-beta Activity in Turkey Erythrocyte Membranes-- Turkey erythrocyte membranes (12.5 µl/assay) were mixed with an equal volume of RGS2 diluted to the indicated concentration in 10 mM Hepes, pH 7.0. Membrane/RGS samples were incubated at 4 °C for 30 min and then added to 2× assay buffer (10 mM Hepes, pH 7.0, 424 µM CaCl2, 910 µM MgSO4, 2 mM EGTA, 115 mM KCl, 5 mM KH2PO4). The assay was initiated by the addition of 25 µl of buffer, GTPgamma S, GTPgamma S with agonist, or GTP with agonist and proceeded at 30 °C for 10 min. The reaction was stopped by the addition of 500 µl of ice-cold CHCl3/MeOH (1:2). 175 µl each of CHCl3 and H2O were added, and the samples were centrifuged at 1800 × g for 5 min. Inositol phosphates were isolated by anion exchange chromatography by transferring 400 µl of the aqueous upper phase to Bio-Rad AG1-X8 (200-400 mesh) columns containing 10 ml of H2O. 10 ml of 200 mM ammonium formate, 100 mM formic acid were added, and the eluate was discarded. Inositol phosphates were eluted with 5 ml of 1.2 M ammonium formate, 100 mM formic acid, and [3H]inositol phosphates were quantitated by liquid scintillation spectrometry.

In Vitro Kinase Reactions-- For experiments with the mixture of calcium and phospholipid-dependent PKC isozymes or with the individual PKC isoforms (alpha , beta 1, beta 2, and gamma ), histidine-tagged RGS2 (4-18 pmol) was incubated with PKC at 30 °C in a reaction containing 20 mM Tris, pH 7.5, 10 mM MgCl2, 500 µM CaCl2, 100 µg/ml PS, 20 µg/ml 1,2-dioleoyl-sn-glycerol, 200 nM calyculin A, and 200 µM [gamma -32P]ATP (~1500 cpm/pmol) in a final volume of 20 µl. Concentrations of PKC and incubation times are as listed in the figure legends. One unit of PKC activity is defined as the amount of enzyme required to transfer 1 µmol of phosphate from ATP to histone H1 per min at 30 °C. Reactions were terminated by the addition of 20 µl of 2× Laemmli sample buffer. Samples were separated by SDS-PAGE through 12.5% acrylamide according to the method of Laemmli (20), and the protein bands were visualized by silver or Coomassie stain. The gel was dried and exposed to autoradiography film to detect radioactive bands. For experiments to test the capacity of phosphorylated RGS2 to inhibit Galpha 11 signaling, RGS2 was phosphorylated by the PKC catalytic subunit, which does not require calcium and phospholipids for activation. Purified RGS2 (~40 pmol) was incubated with the PKC catalytic subunit at 30 °C in a reaction containing 50 mM MES, pH 6.0, 12.5 mM MgCl2, 1.25 mM EGTA, 200 nM calyculin A, and 125 µM ATP in a final volume of 16 µl. Concentrations of PKC and incubation times are as indicated in the figure legends. Reaction mixtures were diluted in 10 mM Hepes, pH 7.0, 10 mM beta -glycerophosphate, 200 nM calyculin A, and bovine serum albumin (2 mg/ml) and mixed with turkey erythrocyte membranes at 4 °C for 30 min to obtain the indicated concentrations of RGS2. Membrane samples were assayed for inositol phosphate production as described above. beta -Glycerophosphate and calyculin A were included in PLC assays with phosphorylated RGS2 to inhibit phosphatase activity.

[32P]Pi Labeling and Isolation of RGS2 from Mammalian Cells-- COS7 cells were transiently transfected using FuGENE transfection reagent and His10-RGS2 plasmid DNA (4 µg/100-mm plate), essentially as directed by the manufacturer. Forty-eight h post-transfection, phosphate-free DMEM (4 ml/100-mm plate) was applied for 1 h at 37 °C, and the medium was supplemented with 500 µCi of [32P]Pi for an additional 3 h. Drugs were added directly to the medium as indicated, and incubation at 37 °C continued for 20 min. Following drug treatment, the medium was aspirated, and the cells were lysed isotonically in 1 ml of lysis buffer (20 mM Tris, pH 7.5, 1% Triton X-100, 10% glycerol, 137 mM NaCl, 5 mM beta -mercaptoethanol, 5 mM NaF, 10 mM beta -glycerophosphate, 10 nM microcystin, 200 µM phenylmethylsulfonyl fluoride, 10 µM tosylphenyl chloromethyl ketone, 1 µM pepstatin A, 2 µM leupeptin), and the lysates were centrifuged at 35,000 × g for 30 min. The resulting supernatant (1 ml) was incubated with 25-50 µl of Ni2+-NTA resin with mixing for 1 h at 4 °C to isolate His10-tagged RGS2. The Ni2+-NTA resin was pelleted by centrifugation at 13,000 × g for 15 s, and the supernatant was aspirated. The pellet was washed three times with 25 mM imidazole, three times with 50 mM imidazole, and two times with 75 mM imidazole. RGS2 was eluted from the resin twice with 100 µl of 250 mM imidazole. Isolated proteins were resolved by SDS-PAGE (12.5% (w/v) gel) and subjected to protein staining or transferred electrophoretically to nitrocellulose. RGS2 was detected by Coomassie staining or by Western blot with an anti-penta-His monoclonal antibody. 32P incorporation into RGS2 was assessed by autoradiography and PhosphorImager analysis (Molecular Dynamics, Inc., Sunnyvale, CA).

GTPase Assays-- Purified recombinant human P2Y1 receptor2 was reconstituted with Galpha q and Gbeta 1gamma 2 into proteoliposomes by a modification of the method described by Brandt et al. (21). Briefly, 15 pmol of P2Y1 receptor, 40 pmol of Galpha q, and 150 pmol of Gbeta 1gamma 2 were combined with a mixture of phosphatidylethanolamine, phosphatidylserine, and cholesterol hemisuccinate in detergent solution. Proteoliposomes were formed by Sephadex G-50 gel filtration. RGS2 was phosphorylated by PKC essentially as described above and diluted ~20-fold to the indicated final concentrations in the assay. GTPase activity of the proteoliposomes was determined in the presence of either phosphorylated or mock-phosphorylated RGS2, with or without 100 µM 2MeSADP. Assays were incubated for 30 min at 30 °C and contained 20 mM Hepes, pH 8.0, 50 mM NaCl, 2 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 10 mM beta -glycerophosphate, 10 nM microcystin, and 2 µM [gamma -32P]GTP (~4500 cpm/pmol). The assays were terminated by the addition of 950 µl of a 4 °C solution of 5% activated charcoal in 20 mM H3PO4. Following centrifugation, liberated [32P]Pi in the supernatant was quantified in a liquid scintillation counter.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Others reported previously that recombinant RGS2 blocks GTPgamma S-stimulated Galpha q activation of PLC-beta in NG-108 cell membranes and in reconstitution assays with purified Galpha q and PLC-beta 1 (7). However, the effects of RGS2 on Galpha q signaling activity in the presence of GTP (i.e. under conditions where Galpha q GTPase activity is operative) have not been fully characterized. We have modified an established turkey erythrocyte membrane assay to investigate and compare the capacities of RGS23 to inhibit GTP and GTPgamma S-stimulated PLC-beta t activation. RGS2 was mixed with erythrocyte membranes at various concentrations, and incubations were carried out in the presence of aluminum fluoride, GTP plus 2MeSATP, GTPgamma S plus 2MeSATP, or GTPgamma S alone. RGS2 inhibited aluminum fluoride (IC50 = 10 nM), GTP (IC50 = 14 nM, with 2MeSATP) and GTPgamma S-stimulated (IC50 = 192 and 223 nM, in the presence and absence of 2MeSATP, respectively) PLC-beta t activity in a concentration-dependent manner. However, the aluminum fluoride- and 2MeSATP plus GTP-promoted responses were inhibited by 10-20-fold lower concentrations of RGS2 than those necessary to inhibit GTPgamma S-stimulated PLC activity, both in the presence and absence of the P2Y1 receptor agonist 2MeSATP (Fig. 1). Inositol lipid signaling in the turkey erythrocyte is also stimulated by isoproterenol through Galpha 11 coupling to a beta -adrenergic receptor (22-24). RGS2 attenuated isoproterenol plus GTPgamma S-stimulated inositol phosphate production half-maximally at an RGS concentration ~20-fold lower than that observed with 2MeSATP plus GTPgamma S stimulation (Fig. 2). Although the mechanism underlying this difference in potency has not been fully investigated, this result suggests a receptor-selective component to inhibition by RGS2.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of PLC-beta activation in turkey erythrocyte membranes by RGS2. Turkey erythrocyte membranes were radiolabeled overnight in inositol-free DMEM with 0.5 mCi [3H]inositol, and membranes were prepared by hypotonic lysis as described under "Experimental Procedures." Membranes were incubated with the indicated concentrations of RGS2 for 30 min at 4 °C, and PLC activity was assayed as described. Reactions were initiated by the addition of aluminum fluoride (A), 10 µM 2MeSATP plus 1 mM GTP (B), 10 µM 2MeSATP plus 10 µM GTPgamma S (C), or 100 µM GTPgamma S (D). The IC50 values for RGS2 obtained in A-D are summarized in E. Basal levels of inositol phosphate production with 10 mM Hepes, pH 7.0, were subtracted from the values presented. Data are mean ± S.D. of triplicate determinations and are representative of three experiments.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Inhibition of beta -adrenergic receptor-mediated PLC-beta activation in turkey erythrocyte membranes by RGS2. A, turkey erythrocyte membranes were radiolabeled overnight in inositol-free DMEM with 0.5 mCi of [3H]inositol, and membranes were prepared by hypotonic lysis as described under "Experimental Procedures." Membranes were incubated with the indicated concentrations of RGS2 for 30 min at 4 °C, and PLC activity was assayed as described. Reactions were initiated by the addition of 100 µM isoproterenol (ISO) plus 10 µM GTPgamma S () or 10 µM 2MeSATP plus 10 µM GTPgamma S (). B, comparison of the IC50 values of RGS2 for inhibition of purinergic and beta -adrenergic receptor-mediated activation of PLC-beta t. Basal levels of inositol phosphate production with 10 mM Hepes, pH 7.0, were subtracted from the values presented. Data are mean ± S.D. of triplicate determinations and are representative of three experiments.

Activation of PKC either indirectly through Ca2+-mobilizing receptors or directly by phorbol esters results in desensitization of receptor and G protein-promoted phosphoinositide hydrolysis (25). Utilizing a turkey erythrocyte membrane reconstitution assay, we previously reported that activation of PKC in intact cells inhibits the capacity of Galpha 11 to activate purified PLC-beta 1. While the effects of PKC were localized to the membrane, we were unable to identify the membrane target for PKC (18). Therefore, since the erythrocyte membrane assay provides a reliable assay of Galpha 11-interacting RGS proteins, we determined if RGS2 was a substrate for PKC in vitro and utilized the erythrocyte assay to identify phosphorylation-dependent changes in RGS-promoted attenuation of inositol phosphate production. RGS2 was phosphorylated to a stoichiometry near unity (0.77 ± 0.25 mol phosphate/mol RGS2) by a bovine brain preparation consisting of a mixture of PKC isoforms (Fig. 3). Individual calcium and phospholipid-dependent PKC isoforms (alpha , beta 1, beta 2, and gamma ) were also utilized and phosphorylated RGS2 to approximately the same level (Fig. 3). Minimal phosphorylation was detected in the absence of PKC, indicating that little or no endogenous kinase activity was present in the preparation of RGS2. The extent of phosphorylation of RGS2 was dependent on PKC concentration (Fig. 4A) and the time of incubation (Fig. 4B).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Phosphorylation of RGS2 by PKC. RGS2 (17 pmol) was incubated with 20 microunits of a mixture of calcium and phospholipid-dependent PKC isoforms (Mix) or with individual purified PKC isoforms (alpha , beta 1, beta 2, and gamma ) for 30 min at 30 °C as described under "Experimental Procedures." The reaction products were separated by SDS-PAGE, stained with Coomassie Blue, and exposed to x-ray film. Autoradiography results are presented and are representative of two or three experiments.



View larger version (53K):
[in this window]
[in a new window]
 
Fig. 4.   Time and concentration dependence of PKC-promoted phosphorylation of RGS2. Purified RGS2 (4-9 pmol) was incubated at 30 °C with (A) the specified concentrations of PKC for 30 min or (B) 20 microunits of the calcium and phospholipid-dependent PKC for the indicated times as described under "Experimental Procedures." Reactions were stopped by the addition of SDS-PAGE sample buffer, and the samples were processed as described in the legend to Fig. 2. Autoradiography results are presented and are representative of more than three experiments.

Due to lack of an antibody for immunoprecipitation of RGS2 from turkey erythrocytes, in vivo phosphorylation could not be assessed in these cells. However, a histidine-tagged RGS2 construct for expression in mammalian cells was engineered (see "Experimental Procedures") that permitted isolation of RGS2 from cell lysates with Ni2+-NTA resin. COS7 cells were transiently transfected with His10-RGS2 and radiolabeled with [32P]Pi. Treatment of cells with PMA resulted in a concentration-dependent increase in phosphorylation of RGS2 (Fig. 5A), indicating PKC-dependent phosphorylation of RGS2 in intact cells. Pharmacological analysis indicates that COS7 cells possess an endogenous P2Y2 receptor that couples to Gq to initiate phosphoinositide hydrolysis and subsequently activate PKC. Incubation of 32P-labeled COS7 cells expressing RGS2 with the P2Y2 receptor agonist UTP also resulted in an ~80% increase in RGS2 phosphorylation (Fig. 5B), indicating that physiological activation of PKC through a G protein-coupled receptor promotes in vivo phosphorylation of RGS2.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   In vivo phosphorylation of RGS2. COS7 cells transiently expressing His10-RGS2 were radiolabeled with [32P]Pi and were treated as described under "Experimental Procedures" with vehicle (Me2SO) or the indicated concentrations of PMA (A) or 100 µM UTP (B) for 20 min at 37 °C. The cells were lysed isotonically, and RGS2 was isolated with Ni2+-NTA resin as described. Proteins were separated by SDS-PAGE, and RGS2 protein was detected by immunoblotting with an anti-His antibody (A). SDS-polyacrylamide gels were exposed to film or a PhosphorImager screen for 32P detection. 32P incorporation into RGS2 was quantitated as arbitrary PhosphorImager units (B). The autoradiograms are representative of three experiments, and the bar graphs present the mean ± S.E. of results quantitated and averaged from three separate experiments.

To determine the effect of phosphorylation by PKC on the capacity of RGS2 to attenuate activation of PLC-beta t, RGS2 was phosphorylated to a stoichiometry near unity by PKC in vitro and reconstituted at the indicated concentrations with erythrocyte membranes as described above. Nonphosphorylated RGS2, which was incubated in a standard kinase reaction lacking PKC, inhibited GTP plus 2MeSATP-stimulated inositol phosphate production in a concentration dependent manner (Fig. 6A), consistent with that observed with untreated RGS2 (Fig. 1B). Phosphorylation by PKC decreased the capacity of RGS2 to inhibit GTP-stimulated phosphoinositide hydrolysis (Fig. 6A). Concentration of PKC-dependent increases in phosphorylation of RGS2 (Fig. 4A) resulted in proportional decreases in RGS2-promoted attenuation of 2MeSATP plus GTP-stimulated inositol lipid signaling (Fig. 6B). Time-dependent increases in RGS2 phosphorylation (Fig. 4B) also produced corresponding decreases in RGS2-mediated inhibition of GTP-promoted inositol phosphate production (Fig. 6C).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of phosphorylation by PKC on the inhibition of purinergic receptor-stimulated inositol phosphate production by RGS2. Purified RGS2 was incubated with 22 microunits of the catalytic subunit of PKC () or enzyme buffer () for 30 min at 30 °C (A), the indicated concentrations of the PKC catalytic subunit for 30 min at 30 °C (B), or 22 microunits of PKC for the indicated times at 30 °C (C). Kinase reactions were diluted in 10 mM Hepes, 10 mM beta -glycerophosphate, 200 nM calyculin A, and bovine serum albumin (2 mg/ml) and mixed with turkey erythrocyte membranes at an RGS2 concentration of 10 nM (B and C) or as indicated in the figure (A). Erythrocyte membrane/RGS2 samples were challenged with 10 µM 2MeSATP plus 1 mM GTP for 10 min at 30 °C. Values are presented as percentages of agonist-induced inositol phosphate production in the absence of RGS2 (3539 ± 93 cpm (A); 4793 ± 144 cpm (B); 2159 ± 278 cpm (C)). Basal levels of inositol phosphate production with 10 mM Hepes, pH 7.0, were subtracted from the values presented. Data are mean ± S.D. of triplicate determinations and are representative of 2-4 experiments.

The effect of phosphorylation by PKC on the activity of RGS2 was also determined under conditions where the RGS protein functions as an inhibitor of G protein/effector interaction but not as a GAP (i.e. in the presence of GTPgamma S). The significantly higher concentrations of RGS2 required to inhibit GTPgamma S alone and GTPgamma S plus 2MeSATP-stimulated PLC-beta t activation (Fig. 1, C-E) limited our capacity to test the effect of phosphorylation on RGS2 activity with the nonhydrolyzable GTP analog under these conditions. However, the observation that RGS2 is a significantly more potent inhibitor of GTPgamma S-stimulated inositol phosphate production in the presence of isoproterenol than with 2MeSATP (Fig. 2) provided conditions for studying the capacity of RGS2 to inhibit PLC-beta t activation promoted by a nonhydrolyzable GTP analog. Nonphosphorylated RGS2 attenuated isoproterenol plus GTPgamma S-stimulated inositol phosphate production in a concentration-dependent manner, and phosphorylation by PKC increased the concentration of RGS2 required for half-maximal inhibition of PLC-beta t activation (Fig. 7A). The extent of the reversal of RGS2-mediated attenuation of inositol phosphate production correlated with the concentration of PKC (Fig. 7B) and time of incubation with PKC (Fig. 7C), consistent with a phosphorylation-dependent inhibition of RGS2 activity.



View larger version (12K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of phosphorylation by PKC on the inhibition of beta -adrenergic receptor-stimulated inositol phosphate production by RGS2. Purified RGS2 was incubated with 22 microunits of the catalytic subunit of PKC () or enzyme buffer () for 30 min at 30 °C (A), the indicated concentrations of the PKC catalytic subunit for 30 min at 30 °C (B), or 22 microunits of PKC for the indicated times at 30 °C (C). Kinase reactions were diluted in 10 mM Hepes, 10 mM beta -glycerophosphate, 200 nM calyculin A, and bovine serum albumin (2 mg/ml) and mixed with turkey erythrocyte membranes at an RGS2 concentration of 10 nM (B and C) or as indicated in the figure (A). Erythrocyte membrane/RGS2 samples were challenged with 100 µM isoproterenol (ISO) plus 10 µM GTPgamma S for 10 min at 30 °C. Values are presented as percentages of agonist-induced inositol phosphate production in the absence of RGS2 (7330 ± 432 cpm (A); 10,780 ± 1595 cpm (B); 13498 ± 690 cpm (C)). Basal levels of inositol phosphate production with 10 mM Hepes, pH 7.0, were subtracted from the values presented. Data are mean ± S.D. of triplicate determinations and are representative of 2-4 experiments.

The mechanism of phosphorylation-dependent inhibition of RGS2 activity was further investigated via steady-state GTPase assays performed in proteoliposomes. Phosphorylated or mock-phosphorylated RGS2 was incubated with proteoliposomes containing purified P2Y1 receptor and Galpha qbeta 1gamma 2. The addition of unphosphorylated RGS2 and the P2Y1 receptor agonist 2MeSADP stimulated GTP hydrolysis ~4-fold above the level observed with RGS2 alone (Fig. 8). Phosphorylation significantly reduced RGS2-promoted GTPase activity both in the presence and absence of agonist, demonstrating a phosphorylation-dependent inhibition of the GAP activity of RGS2.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 8.   Phosphorylation-dependent inhibition of RGS2 GAP activity in P2Y1 receptor/Galpha qbeta gamma vesicles. Purified RGS2 (7 µg) was incubated with 40 microunits of the PKC catalytic subunit or enzyme buffer for 30 min at 30 °C in a total reaction volume of 48 µl. Kinase reactions were diluted prior to use in the GTPase assay. Phosphorylated (solid bars) or mock-phosphorylated RGS2 (open bars) was added at a final concentration of 316 nM to proteoliposomes containing purified recombinant human P2Y1 receptor and Galpha qbeta 1gamma 2, and GTPase activity was measured in the presence or absence of 100 µM 2MeSADP. Following a 30-min incubation at 30 °C, the assay was terminated by the addition of 5% activated charcoal in 20 mM H3PO4. The samples were centrifuged, and liberated [32P]Pi in the supernatant was quantitated by liquid scintillation spectrometry. Data are mean ± S.D. of six measurements and are representative of two experiments.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

RGS proteins inhibit heterotrimeric G protein signaling by functioning as both GAPs and effector antagonists (1-3). Previous studies have demonstrated that RGS2 acts as a GAP for Galpha q (8) and attenuates GTPgamma S-stimulated PLC-beta activity (7). In the present study, we have examined the capacity of RGS2 to regulate inositol lipid signaling under conditions where GTPase promoted hydrolysis was operative and have established that RGS2 is a much more potent inhibitor of P2Y receptor-stimulated PLC-beta activity in the presence of GTP than in the presence of the hydrolysis-resistant GTP analog GTPgamma S. Similar concentrations of RGS2 were required for half-maximal inhibition of GTP-stimulated inositol lipid signaling and that occurring in the presence of aluminum fluoride, which mimics the structure of the alpha  subunit at the transition state of the GTPase reaction (26). Thus, RGS2 is a more potent inhibitor of inositol lipid signaling under conditions in which the G protein alpha  subunit exists in the GTPase transition state, either transiently (GTP-promoted signaling) or stably (aluminum fluoride-stimulated signaling). Our results are consistent with the observation that RGS proteins interact with higher affinity to the GDP-AlF4- complex than to the GTPgamma S-bound form of Galpha (5, 27, 28).

Zeng et al. (29) and Xu et al. (30) recently reported receptor-selective inhibition by RGS4 of calcium release and PLC activity in pancreatic acinar cells dialyzed with RGS4. Galpha 11-mediated inositol lipid signaling in the turkey erythrocyte membrane model is stimulated by both P2Y1 and beta -adrenergic receptors (22-24), and thereby provides conditions for more directly investigating potential receptor-selective activity of RGS2. RGS2 inhibited isoproterenol plus GTPgamma S-stimulated inositol phosphate production half-maximally at RGS concentrations 20-fold lower than those observed with 2MeSATP and GTPgamma S. While our results do not reveal the mechanism underlying these differences in RGS2 potency, they suggest the occurrence of receptor-selective activity of RGS2. The N-terminal domain of RGS4 was proposed to impart high affinity and receptor-selective inhibition of Gq signaling (29). Little similarity exists between the N-terminal domain of RGS4 and RGS2, and it will be important to establish the basis of the apparent receptor selectivity found in our study with RGS2.

PKC is activated as a downstream consequence of PLC activation and has been implicated in regulation of inositol lipid signaling (25). We previously demonstrated that membranes isolated from turkey erythrocytes pretreated with PMA exhibit a decreased capacity for Galpha 11-mediated activation of purified, reconstituted PLC-beta 1 (18). Additionally, we illustrated that PLC-beta t is phosphorylated in intact erythrocytes in response to PMA treatment, and in vitro phosphorylation of PLC-beta t by PKC reduces its basal catalytic activity (17). We demonstrate here that RGS2 is phosphorylated stoichiometrically by PKC in vitro and in intact mammalian cells stimulated with PMA or the P2Y2 receptor agonist UTP. Phosphorylation decreases the capacity of reconstituted RGS2 to attenuate PLC-beta t activity in turkey erythrocyte membranes and significantly reduces RGS2 GAP activity in P2Y1 receptor/Galpha qbeta gamma vesicles, supporting a role for phosphorylation in regulation of RGS protein activity. This result may be surprising in light of the general conception that RGS proteins have a "desensitizing" activity on G protein-mediated signaling and the observations in our laboratory and numerous others illustrating that PKC activation generally promotes desensitization of inositol lipid signaling (31-34). Phosphorylation of RGS2 by PKC would potentiate receptor-stimulated inositol lipid hydrolysis, and therefore, our results suggest that inositol lipid signaling in vivo is regulated temporally by a balance of PKC-promoted inhibitory and stimulatory signals. Such a view is not inconsistent with reports suggesting that receptor-promoted phospholipid signaling is not simply a result of straightforward negative feedback regulation by PKC. Rapid desensitization of phosphoinositide hydrolysis is often only partial and accumulation of inositol 1,4,5-trisphosphate is biphasic (35-37). Moreover, levels of intracellular calcium have been shown to oscillate in the presence of hormone (38-41), and PKC has been strongly implicated in these calcium oscillations (42-45). Thus, studies of both receptor-promoted inositol 1,4,5-trisphosphate production and intracellular calcium levels are consistent with the concept that the role of PKC in regulating phosphoinositide hydrolysis may be more complex than mere signal inactivation.

PKC is activated as a consequence of signaling events other than Gq-promoted phosphoinositide hydrolysis, and phospholipid signaling does not occur in isolation in the intact cell. Thus, in vivo phosphorylation of RGS2 may be involved in cross-talk regulation between signaling pathways. More detailed studies will be needed to determine whether involvement of different PKC isoforms with different temporal patterns of activation and substrate selectivities also underlies our observations with PKC-promoted phosphorylation of RGS2.

Precedent exists for sensitivity of RGS protein-G protein interactions to protein phosphorylation state. Galpha z is phosphorylated by PKC in vitro, thereby reducing the capacity of RGSZ1 to accelerate Galpha z GTPase activity (46, 47). The effect of Galpha z phosphorylation on its interaction with RGSZ1 also suggests that stimulation of PKC potentiates Galpha z signaling by lengthening the time that the G protein remains in the active GTP-bound conformation. Therefore, while the target of PKC-promoted phosphorylation in our study is the RGS protein rather than the G protein, the observation that PKC-mediated phosphorylation of RGS2 decreases its capacity to attenuate Galpha 11 signaling is consistent with the sensitivity of RGS-G protein interactions to phosphorylation demonstrated with Galpha z and RGSZ1. Phosphorylation of RGS2 decreased its ability to inhibit GTP-promoted PLC-beta t activation and its capacity to promote GTP hydrolysis in vesicles containing the P2Y1 receptor and Galpha qbeta gamma . In addition to inhibition of RGS2 activities under conditions where GTPase activity was operative, phosphorylation also attenuated RGS2 inhibition of GTPgamma S-stimulated signaling. While the details of the association are still unclear, these observations suggest that PKC-promoted phosphorylation of RGS2 affects interactions with Galpha q/11 in such a way that RGS2 cannot promote GTPase activity or block Galpha q/11 interactions with its effector PLC-beta as effectively as in the nonphosphorylated state.

Phosphorylation may provide a common method of regulation of RGS proteins, impacting on both their subcellular localization and their GAP activity. Pedram et al. (48) observed phosphorylation of RGS3 and RGS4 by cGMP-dependent protein kinase and implicated phosphorylation in translocation of these RGS proteins from a cytosolic to a membrane localization. Farquhar and colleagues reported that membrane-associated GAIP, but not soluble GAIP, exists as a phosphoprotein and that GAIP can be phosphorylated in vitro by purified casein kinase 2 and by isolated clathrin-coated vesicles (49). Benzing et al. (50) recently reported PKC-promoted phosphorylation of RGS7 and phosphorylation-dependent association of RGS7 and 14-3-3 proteins. Moreover, binding of 14-3-3 to phosphorylated RGS7 inhibited the capacity of RGS7 to promote GTP hydrolysis by Galpha i. Interestingly, several of the residues in the putative 14-3-3 binding motif of RGS7, including the serine residue phosphorylated by PKC, are conserved in RGS2 and other RGS proteins, suggesting another possible level of RGS2 regulation by PKC in the intact cell. Although the precise mechanisms have not been fully elucidated, phosphorylation by PKC probably plays an important role in regulating cellular RGS2 activity.


    ACKNOWLEDGEMENTS

We are indebted to Dr. Josè Boyer and Dr. Scott Heximer for helpful discussions and advice.


    FOOTNOTES

* This work was supported by United States Public Health Service Grants GM29536 and GM38213 and a Howard Hughes Medical Institute Predoctoral Fellowship (to M. L. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: CB# 7365, Mary Ellen Jones Bldg., University of North Carolina School of Medicine, Chapel Hill, NC 27599. Tel.: 919-966-5356; Fax: 919-966-5640; E-mail: tkh@med.unc.edu.

Published, JBC Papers in Press, November 3, 2000, DOI 10.1074/jbc.M007699200

2 G. L. Waldo and T. K. Harden, manuscript in preparation.

3 Human RGS2 was used in this study; however, we have cloned turkey RGS2, which is ~69% identical and 80% homologous to the human homologue (G. L. Waldo and T. K. Harden, unpublished observations).


    ABBREVIATIONS

The abbreviations used are: G protein, guanine nucleotide-binding protein; PKC, protein kinase C; PLC, phospholipase C; GTPgamma S, guanosine 5'-O-thiophosphate; DMEM, Dulbecco's modified Eagle's medium; PAGE, polyacrylamide gel electrophoresis; 2MeSADP, 2-methylthioadenosine diphosphate; 2MeSATP, 2-methylthioadenosine triphosphate; PMA, 4beta -phorbol 12beta -myristate 13alpha -acetate; GAP, GTPase-activating protein; NTA, nitrilotriacetic acid; MES, 4-morpholineethanesulfonic acid.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Dohlman, H. G., and Thorner, J. (1997) J. Biol. Chem. 272, 3871-3874[Free Full Text]
2. Berman, D. M., and Gilman, A. G. (1998) J. Biol. Chem. 273, 1269-1272[Free Full Text]
3. De Vries, L., and Farquhar, M. G. (1999) Trends Cell Biol. 9, 138-144[CrossRef][Medline] [Order article via Infotrieve]
4. Hepler, J. R. (1999) Trends Pharmacol. Sci. 20, 376-382[CrossRef][Medline] [Order article via Infotrieve]
5. Berman, D. M., Wilkie, T. M., and Gilman, A. G. (1996) Cell 86, 445-452[Medline] [Order article via Infotrieve]
6. Hepler, J. R., Berman, D. M., Gilman, A. G., and Kozasa, T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 428-432[Abstract/Free Full Text]
7. Heximer, S. P., Watson, N., Linder, M. E., Blumer, K. J., and Hepler, J. R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14389-14393[Abstract/Free Full Text]
8. Ingi, T., Krumins, A. M., Chidiac, P., Brothers, G. M., Chung, S., Snow, B. E., Barnes, C. A., Lanahan, A. A., Siderovski, D. P., Ross, E. M., Gilman, A. G., and Worley, P. F. (1998) J. Neurosci. 18, 7178-7188[Abstract]
9. Heximer, S. P., Srinivasa, S. P., Bernstein, L. S., Bernard, J. L., Linder, M. E., Hepler, J. R., and Blumer, K. J. (1999) J. Biol. Chem. 274, 34253-34259[Abstract/Free Full Text]
10. Berridge, M. J., and Irvine, R. F. (1987) Annu. Rev. Biochem. 56, 159-193[CrossRef][Medline] [Order article via Infotrieve]
11. Harden, T. K., Stephens, L., Hawkins, P. T., and Downes, C. P. (1987) J. Biol. Chem. 262, 9057-9061[Abstract/Free Full Text]
12. Boyer, J. L., Downes, C. P., and Harden, T. K. (1989) J. Biol. Chem. 264, 884-890[Abstract/Free Full Text]
13. Morris, A. J., Waldo, G. L., Downes, C. P., and Harden, T. K. (1990) J. Biol. Chem. 265, 13501-13507[Abstract/Free Full Text]
14. Morris, A. J., Waldo, G. L., Downes, C. P., and Harden, T. K. (1990) J. Biol. Chem. 265, 13508-13514[Abstract/Free Full Text]
15. Waldo, G. L., Boyer, J. L., Morris, A. J., and Harden, T. K. (1991) J. Biol. Chem. 261, 14217-14225
16. Waldo, G. L., Paterson, A., Boyer, J. L., Nicholas, R. A., and Harden, T. K. (1996) Biochem. J. 316, 559-568[Medline] [Order article via Infotrieve]
17. Filtz, T. M., Cunningham, M. L., Stanig, K. J., Paterson, A., and Harden, T. K. (1999) Biochem. J. 338, 257-264[CrossRef][Medline] [Order article via Infotrieve]
18. Cunningham, M. L., Filtz, T. M., and Harden, T. K. (1999) Mol. Pharmacol. 56, 265-271[Abstract/Free Full Text]
19. Watson, N., Linder, M. E., Druey, K. M., Kehrl, J. H., and Blumer, K. J. (1996) Nature 383, 172-175[CrossRef][Medline] [Order article via Infotrieve]
20. Laemmli, U. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
21. Brandt, D. R., Asano, T., Pedersen, S. E., and Ross, E. M. (1983) Biochemistry 22, 4357-4362[Medline] [Order article via Infotrieve]
22. Rooney, T. A., Hager, R., and Thomas, A. P. (1991) J. Biol. Chem. 266, 15068-15074[Abstract/Free Full Text]
23. Vaziri, C., and Downes, C. P. (1992) Biochem. J. 284, 917-922[Medline] [Order article via Infotrieve]
24. James, S. R., Vaziri, C., Walker, T. R., Milligan, G., and Downes, C. P. (1994) Biochem. J. 304, 359-364[Medline] [Order article via Infotrieve]
25. Fisher, S. K. (1995) Eur. J. Pharmacol. 288, 231-250[CrossRef][Medline] [Order article via Infotrieve]
26. Sondek, J., Lambright, D. G., Noel, J. P., Hamm, H. E., and Sigler, P. B. (1994) Nature 372, 276-279[CrossRef][Medline] [Order article via Infotrieve]
27. Berman, D. M., Kozasa, T., and Gilman, A. G. (1996) J. Biol. Chem. 271, 27209-27212[Abstract/Free Full Text]
28. Tesmer, J. J. G., Berman, D. M., Gilman, A. G., and Sprang, S. R. (1997) Cell 89, 251-261[Medline] [Order article via Infotrieve]
29. Zeng, W., Xu, X., Popov, S., Mukhopadhyay, S., Chidiac, P., Swistok, J., Danho, W., Yagaloff, K. A., Fisher, S. L., Ross, E. M., Muallem, S., and Wilkie, T. M. (1998) J. Biol. Chem. 273, 34687-34690[Abstract/Free Full Text]
30. Xu, X., Zeng, W., Popov, S., Berman, D. M., Davignon, I., Yu, K., Yowe, D., Offermanns, S., Muallem, S., and Wilkie, T. M. (1999) J. Biol. Chem. 274, 3549-3556[Abstract/Free Full Text]
31. Rittenhouse, S. E., and Sasson, J. P. (1985) J. Biol. Chem. 260, 8657-8660[Abstract/Free Full Text]
32. Orellana, S. A., Solski, P. A., and Brown, J. H. (1985) J. Biol. Chem. 260, 5236-5239[Abstract]
33. Orellana, S. A., Solski, P. A., and Brown, J. H. (1987) J. Biol. Chem. 262, 1638-1643[Abstract/Free Full Text]
34. Hepler, J. R., Earp, H. S., and Harden, T. K. (1988) J. Biol. Chem. 263, 7610-7619[Abstract/Free Full Text]
35. Menniti, F. S., Takemura, H., Oliver, K. G., and Putney, J. W. (1991) Mol. Pharmacol. 40, 727-733[Abstract]
36. Fisher, S. K., Slowiejko, D. M., and McEwen, E. L. (1994) Neurochem. Res. 19, 549-554[Medline] [Order article via Infotrieve]
37. Wojcikiewicz, R. J. H., Tobin, A. B., and Nahorski, S. R. (1994) J. Neurochem. 63, 177-185[Medline] [Order article via Infotrieve]
38. Woods, N. M., Cuthbertson, K. S. R., and Cobbold, P. H. (1986) Nature 319, 600-602[Medline] [Order article via Infotrieve]
39. Berridge, M. J., and Galione, A. (1988) FASEB J. 2, 3074-3082[Abstract/Free Full Text]
40. Cobbold, P. H., and Cuthbertson, K. S. (1990) Semin. Cell Biol. 1, 311-321[Medline] [Order article via Infotrieve]
41. Cobbold, P. H., Sanchez-Bueno, A., and Dixon, C. J. (1991) Cell Calcium 12, 87-95[Medline] [Order article via Infotrieve]
42. Woods, N. M., Cuthbertson, K. S., and Cobbold, P. H. (1987) Biochem. J. 246, 619-623[Medline] [Order article via Infotrieve]
43. Bird, G. S. J., Rossier, M. F., Obie, J. F., and Putney, J. W. (1993) J. Biol. Chem. 268, 8425-8428[Abstract/Free Full Text]
44. Sanchez-Bueno, A., Dixon, C. J., Woods, N. M., Cuthbertson, K. S., and Cobbold, P. H. (1990) Biochem. J. 268, 627-632[Medline] [Order article via Infotrieve]
45. Berrie, C. P., and Cobbold, P. H. (1995) Cell Calcium 18, 232-244[CrossRef][Medline] [Order article via Infotrieve]
46. Glick, J. L., Meigs, T. E., Miron, A., and Casey, P. J. (1998) J. Biol. Chem. 273, 26008-26013[Abstract/Free Full Text]
47. Wang, J., Ducret, A., Tu, W., Kozasa, T., Aebersold, R., and Ross, E. M. (1998) J. Biol. Chem. 273, 26014-26025[Abstract/Free Full Text]
48. Pedram, A., Razandi, M., Kehrl, J., and Levin, E. R. (2000) J. Biol. Chem. 275, 7365-7372[Abstract/Free Full Text]
49. Fischer, T., Elenko, E., Wan, L., Thomas, G., and Farquhar, M. G. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4040-4045[Abstract/Free Full Text]
50. Benzing, T., Yaffe, M. B., Arnould, T., Sellin, L., Schermer, B., Schilling, B., Schreiber, R., Kunzelmann, K., Leparc, G. G., Kim, E., and Walz, G. (2000) J. Biol. Chem. 275, 28167-28172[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.